Press Releases for BIIB

Press Releases
Analyst Choice Updated Analysis on DENTSPLY International Inc., PAETEC Holding Corp., Antigenics Inc., Cubist Pharmaceuticals Inc., Alkermes Inc. and Biogen Idec Inc.
Sunesis Reports Financial Results for the Second Quarter 2009
Biogen Idec Reports Second Quarter 2009 Results
Phillip A. Sharp to Retire from Biogen Idec Board
InvestorSoup.com Issues Trading Outlook for Hemispherex Biopharma Inc.
Finesse Solutions Forges Agreement With Leading Biotechnology Company for Single-Use Technology Exploration
Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec
Biogen Idec Receives Fast Track Designation from FDA for PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis
Biogen Idec to Report Second Quarter 2009 Financial Results on July 16, 2009
Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
Biogen Idec Announces First Patient Enrolled in the Global Phase III Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis
Biogen Idec Announces Conclusion of Arbitration with Genentech
Biogen Idec Announces Preliminary Tabulation of Stockholder Vote by Independent Inspector of Elections
Biogen Idec to Present at the Goldman Sachs 30th Annual Healthcare Conference
Biogen Idec Announces Preliminary Results of Stockholder Vote
MaybachFinancial.Com Posts Free Analyst Report on WY, XTO, BIIB and OSIP
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn’s Disease Patients with Prior Exposure or Inadequate Response to Anti-TNFa Therapy
Biogen Idec Joins with the Global MS Community to Mark World MS Day
Biogen Idec Sends Letter to Stockholders
Biogen Idec Comments on Proxy Advisory Firms’ Reports
Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Biogen Idec to Present at the Deutsche Bank 34th Annual Health Care Conference
First Ten-Year Follow-Up Shows That Treatment with AVONEX® Leads to Long-Term Benefits in Early Multiple Sclerosis Patients
MRI Data Showing TYSABRI® Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology
Biogen Idec Board Recommends Shareholders Elect Directors with Record of Success in Enhancing the Value of the Company
Biogen Idec Reports First Quarter 2009 Results
AnalystChoice.Com Free Investment Opinion on LKQX, JOSB, CRME and BIIB
Beacon Equity Issues Trade Alerts on Market Movers: PIR, CSCO, AA, ADM, BIIB, BBBY
Biogen Idec to Report First Quarter 2009 Financial Results on April 16, 2009
CTI Receives the Second Payment of $6.5 Million Associated With the Sale of Interest in Zevalin Joint Venture - Apr 6 2009 3:58AM
Biogen Idec to Present at the 4(th) Annual Citi Biotech Day
Biogen Idec Names Robert Hamm Chief Operating Officer
Biogen Idec Highlights Progress and Breadth of Pipeline Programs at R&D Day
Biogen Idec Announces March 25 Webcast of Research & Development Day
Biogen Idec Announces Head of Research and Development Dr. Cecil B. Pickett to Retire
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Biogen Idec to Present at the Cowen & Company 29th Annual Healthcare Conference
Zacks Bull and Bear of the Day Highlights: Onyx Pharma, Navigant Consulting, Bristol Myers, Biogen Idec and Strayer Education
Biogen Idec Names Michael Lytton Executive Vice President of Business Development
Zacks Analyst Blog Highlights: Biogen Idec, Ford Motor Company, Tata Motors, United Parcel Service, Inc. And Carmike Cinemas, Inc.
Zacks Bull & Bear of the Day Highlights: Biogen Idec, CEMEX, Ford, Tata Motors and Carmike Cinemas
MS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
BenchmarkJournal.Com (Complimentary) Analyst Review for NVLS, MCRS, BIIB and KFRC
Biogen Idec Reports Full Year and Fourth Quarter 2008 Results
Biogen Idec Receives Shareholder Proposal
Zacks Bull & Bear of the Day Highlights: InterDigital, Overstock.Com, Sanofi-Aventis, Bristol-Myers Squibb and Biogen Idec
Zacks Releases Four Powerful ''Buy'' Stocks: Biogen Idec, NTELOS Holdings Corp., Northwestern Corp. And IDACORP - Jan 21 2009 1:19AM
Biogen Idec to Report Fourth Quarter and Full Year 2008 Financial Results on February 6, 2009
Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Amgen, Intel and AMD
Biogen Idec to Present at the 27th Annual J.P. Morgan Healthcare Conference
Biogen Idec to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Phase III Study Showed Rituxan® Decreased the Progression of Joint Damage in Patients with Early Rheumatoid Arthritis (RA)
Zacks Analyst Blog Highlights: Canadian Pacific Railway Limited, Biogen Idec Inc., Plexus Corp., The Dow Chemical Company, and Jones Lang LaSalle, Incorporated
Biogen Idec to Present at the Lazard Capital Markets Fifth Annual Life Sciences Conference
Biogen Idec to Present at the Credit Suisse 2008 Healthcare Conference
Biogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 Molecule
Rituxan Data in Patients with Rheumatoid Arthritis to Be Presented at the American College of Rheumatology Annual Scientific Meeting
Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis
Biogen Idec Reports Third Quarter 2008 Results
Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis
Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
Biogen Idec to Report Third Quarter 2008 Financial Results on October 21, 2008
Biogen Idec Announces Webcast of Presentation at the UBS Global Life Sciences Conference
Traders Ecstatic With "Stock Alerts" As Trading Profits Reach As High As 20%+
Seven Summits Research Releases Alerts on GE, X, NEM, BIIB, and BG
TYSABRI(R) Demonstrates Sustained Improvement in Functional Outcomes in Multiple Sclerosis Patients According to New Post-Hoc Analysis
New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life
Biogen Idec Features Data on AVONEX(R) and TYSABRI(R) and Showcases the Company's Multiple Sclerosis Development Pipeline at the World Congress On Treatment and Research in Multiple Sclerosis
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Biogen Idec to Present at the 3rd Annual CITI Biotech Day
Biogen Idec to Present at the Thomas Weisel Partners Healthcare Conference
BellwetherReport.Com Analyst Opinions on FSLR, MSFT, SWKS and BIIB
Biogen Idec Initiates Phase III Clinical Trial for ADENTRI(R) in Acute Decompensated Heart Failure Patients with Renal Insufficiency
BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
Biogen Idec and Elan Will Host a Conference Call For the Investment Community
Growth Stock Alert for Tuesday, July 29, 2008: PSTI Moving Forward With the FDA!
Biogen Idec Names Brian S. Posner to Board of Directors
Biogen Idec Reports Second Quarter 2008 Results
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biogen Idec Announces Certified Stockholder Vote Results, Confirming Election of All Four of the Board's Director Nominees
Biogen Idec to Report Second Quarter 2008 Financial Results on July 22, 2008
Biogen Idec Stockholders Elect Company's Board Nominees
Proxy Governance Endorses All Four Biogen Idec Director Nominees
RiskMetrics and Glass Lewis Endorse All Four Biogen Idec Director Nominees
BeaconEquity.com Issues TraderNotes on Biotechnology Stocks: TPIM, RXII, VION, CUR, AMGN, GILD, BIIB, GENR
Biogen Idec Names Hans Peter Hasler Chief Operating Officer
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care - May 27 2008 12:56AM
Biogen Idec Commences Mailing of Proxy Materials to Shareholders - Jun 1 2008 10:53AM
Seven Summits Research Releases Alerts on C, WMT, CAT, BIIB, and BBT - May 27 2008 1:16AM
BellwetherReport.com Initiates Analyst Coverage on TXRH, TRID, HGSI and BIIB - May 27 2008 1:16AM
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Biogen Idec Reports First Quarter 2008 Results
Biogen Idec Announces Slate of Directors for Annual Meeting of Shareholders
Data Presented at the 60th Annual Meeting of the American Academy of Neurology Offers Additional Support for Plasma Exchange as a Potential Tool to Accelerate TYSABRI(R) Removal
Biogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology
Biogen Idec Announces Multiple Sclerosis Franchise and Pipeline Presentations at the 60th Annual Meeting of the American Academy of Neurology
Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis
Biogen Idec to Report First Quarter 2008 Financial Results on April 23, 2008